Non–Small Cell Lung Cancer (NSCLC) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033


 Non-small cell lung cancer (NSCLC) is the predominant variant of lung cancer, comprising most cases. About 18% of these cases pertain to early-stage NSCLC, typically necessitating a multifaceted therapeutic approach to a potential cure. The origins of NSCLC can classified into two distinct categories: factors that could have been avoided and those that were unavoidable. Among the most renowned avoidable risk factors for NSCLC is the inhalation of tobacco, but other contributors encompass alcohol consumption, exposure to secondhand smoke, contact with hazardous substances like asbestos, radon, arsenic, chromium, and nickel, as well as exposure to ionizing radiation and polycyclic aromatic hydrocarbons. Radiation therapy in treating other malignancies, such as breast cancer and Hodgkin lymphoma can also induce primary lung cancer. The suspicion of NSCLC diagnosis typically arises when a patient presents with intrathoracic symptoms and is subsequently found to have a pulmonary nodule on a chest radiograph. Given these intrathoracic symptoms and potential chest radiograph findings, the differential diagnosis encompasses a spectrum of possibilities, including bronchogenic carcinoma (such as adenocarcinoma, squamous cell carcinoma, large cell carcinoma, and small cell carcinoma), metastatic disease from various primary sites, pulmonary carcinoid, extranodal lymphoma, and plasmacytoma or schwannoma. The complications arising from NSCLC are contingent upon the local extent of the disease and the potential involvement of metastases. Intrathoracic complications may manifest as malignant pleural effusion, resulting in dyspnea or respiratory failure, contingent on the pathology's extent and the presence of comorbid conditions. Additionally, non-small cell lung cancer is the predominant malignant cause of superior vena cava (SVC) syndrome, accounting for approximately 50% of all cases. The 5-year overall survival (OS) rate varies from 50% for stage IA disease to 15% for stage IIIA NSCLC. The established treatment approach for patients with stage I and II, as well as IIIA NSCLC, involves surgical resection. Post-resection, patients may be offered adjuvant systemic therapy.

·       In the United States, NSCLC represents the predominant form of lung cancer, making up 81% of all lung cancer diagnoses.

 

Thelansis’s “Non–Small Cell Lung Cancer (NSCLC) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Non–Small Cell Lung Cancer (NSCLC) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

 

KOLs insights of Non–Small Cell Lung Cancer (NSCLC) across 8 MM market from the centre of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs.

Non–Small Cell Lung Cancer (NSCLC) Market Forecast Patient Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.

Thelansis Competitive Intelligence (CI) practice has been established based on a deep understanding of the pharma/biotech business environment to provide an optimized support system to all levels of the decision-making process. It enables business leaders in forward-thinking and proactive decision-making. Thelansis supports scientific and commercial teams in seamless CI support by creating an AI/ ML-based technology-driven platform that manages the data flow from primary and secondary sources.

Read more: Non–Small Cell Lung Cancer (NSCLC) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

Tags: Non–Small Cell Lung Cancer (NSCLC), Non–Small Cell Lung Cancer (NSCLC) market outlook, Non–Small Cell Lung Cancer (NSCLC) competitive landscape, Non–Small Cell Lung Cancer (NSCLC) market forecast, Thelansis, Primary market research, KOL insights, Competitive Intelligence (CI)

Comments

Post a Comment

Popular posts from this blog

Acne Vulgaris – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032

Image
  Acne vulgaris, a prevalent pilosebaceous unit inflammatory skin disorder, follows a persistent course. Typically presenting as papules, pustules, or nodules, it primarily occurs on the face but can also impact the upper arms, trunk, and back. The development of acne results from the sebaceous glands' heightened sensitivity to normal androgen levels, aggravated by Cutibacterium acnes (formerly known as Propionibacterium acnes), a bacterial species that triggers inflammation. The pathogenesis of acne vulgaris involves a complex interplay of factors such as the activation of sebaceous glands by androgens, imbalances in the pilosebaceous follicle microbiome, and cellular immune responses. Genetic predisposition and dietary influences also contribute to the condition's onset and progression. The initial stage is the micro-comedo, a small plug primarily composed of corneocytes in the lower follicular infundibulum. Microcomedones evolve into various acne lesions, including closed co...
Read more

Herpes Simplex Virus (HSV) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

Image
 Herpes simplex virus (HSV) causes an infection that affects the external genitalia, anal region, mucosal surfaces, and skin in other body parts. Herpes simplex virus is a ubiquitous, host-adapted pathogen that causes various disease states. There are two types of HSV with two distinct DNA viruses, type 1 (HSV-1) and type 2 (HSV-2). Both the types are closely related but differ epidemiologically. HSV-1 is traditionally associated with orofacial disease by affecting the mouth and lips with fever blisters and cold sores, whereas HSV-2 is associated traditionally with genital disease infecting genitals and rectum area with sores and is classified as STD (sexually transmitted disease). As HSV-1 is associated with genital infections more often than HSV-2, lesion location is not necessarily of viral type. HSV can spread through direct contact. Almost 80% of Herpes simplex infections are asymptomatic, while symptomatic infections can be characterized by significant morbidity and recurrenc...
Read more

HR+/HER2- Breast Cancer – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

Image
Thelansis’s “HR+/HER2- Breast Cancer Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential HR+/HER2- Breast Cancer treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China). KOLs insights of HR+/HER2- Breast Cancer across 8 MM market from the centre of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs. HR+/HER2- Breast Cancer Market Forecast Patient Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model,...
Read more